Unknown

Dataset Information

0

Inhibition of cancer cell proliferation by PPAR? is mediated by a metabolic switch that increases reactive oxygen species levels.


ABSTRACT: The nuclear receptor peroxisome-proliferation-activated receptor gamma (PPAR?), a transcriptional master regulator of glucose and lipid metabolism, inhibits the growth of several common cancers, including lung cancer. In this study, we show that the mechanism by which activation of PPAR? inhibits proliferation of lung cancer cells is based on metabolic changes. We found that treatment with the PPAR? agonist pioglitazone triggers a metabolic switch that inhibits pyruvate oxidation and reduces glutathione levels. These PPAR?-induced metabolic changes result in a marked increase of reactive oxygen species (ROS) levels that lead to rapid hypophosphorylation of retinoblastoma protein (RB) and cell-cycle arrest. The antiproliferative effect of PPAR? activation can be prevented by suppressing pyruvate dehydrogenase kinase 4 (PDK4) or ?-oxidation of fatty acids in vitro and in vivo. Our proposed mechanism also suggests that metabolic changes can rapidly and directly inhibit cell-cycle progression of cancer cells by altering ROS levels.

SUBMITTER: Srivastava N 

PROVIDER: S-EPMC4191999 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inhibition of cancer cell proliferation by PPARγ is mediated by a metabolic switch that increases reactive oxygen species levels.

Srivastava Nishi N   Kollipara Rahul K RK   Singh Dinesh K DK   Sudderth Jessica J   Hu Zeping Z   Nguyen Hien H   Wang Shan S   Humphries Caroline G CG   Carstens Ryan R   Huffman Kenneth E KE   DeBerardinis Ralph J RJ   Kittler Ralf R  

Cell metabolism 20140925 4


The nuclear receptor peroxisome-proliferation-activated receptor gamma (PPARγ), a transcriptional master regulator of glucose and lipid metabolism, inhibits the growth of several common cancers, including lung cancer. In this study, we show that the mechanism by which activation of PPARγ inhibits proliferation of lung cancer cells is based on metabolic changes. We found that treatment with the PPARγ agonist pioglitazone triggers a metabolic switch that inhibits pyruvate oxidation and reduces glu  ...[more]

Similar Datasets

2014-09-25 | E-GEOD-59736 | biostudies-arrayexpress
2014-09-25 | GSE59736 | GEO
| S-EPMC5484671 | biostudies-literature
| S-EPMC4614431 | biostudies-literature
| S-EPMC10042539 | biostudies-literature
| S-EPMC5926825 | biostudies-literature
| S-EPMC5688167 | biostudies-literature
2020-09-15 | GSE157912 | GEO
| S-EPMC2744635 | biostudies-literature
| S-EPMC6047776 | biostudies-literature